bendamustine + fludarabine

This combination chemotherapy regimen, consisting of the alkylating agent bendamustine and the purine analog fludarabine, is utilized as a lymphodepleting conditioning treatment. In the context of clinical trials conducted by the UNC Lineberger Comprehensive Cancer Center, it is administered to patients with relapsed or refractory CD30+ Hodgkin lymphoma prior to the infusion of investigational CAR-T cell therapies like ATLCAR.CD30.CCR4. The primary goal of this regimen is to reduce the number of endogenous T cells, thereby minimizing competition for homeostatic cytokines and enhancing the expansion, persistence, and anti-tumor activity of the subsequently administered engineered cells. Bendamustine acts by forming covalent bonds with DNA, leading to cross-links and strand breaks, while fludarabine interferes with DNA synthesis and repair by inhibiting key enzymes such as DNA polymerase and ribonucleotide reductase.

Other names

bendamustine and fludarabinelymphodepletion chemotherapyconditioning chemotherapyFlu/Ben